This webinar will review key findings and outcomes from the largest phase 3 study to be conducted in epidermolysis bullosa (EB), the EASE study. This study evaluated the efficacy and safety of birch bark extract, also known as Oleogel-S10, for the treatment of partial thickness wounds in dystrophic and junctional EB.
This webinar will spotlight:
- An overview of EB.
- A summary of the EASE study design, aims, key endpoint, safety and long-term data.
- The implications of the findings from EASE for clinical practice, patients and care givers.
This engaging webinar will also include a live question-and-answer segment, where our expert speakers will consider key questions from the audience and provide specialist perspectives and insights relating to EB and the EASE study.
Register for this webinar:
This medical webinar is sponsored by Amryt Pharma
The information presented is intended for non-promotional scientific purposes only and may contain information on products or indications currently under investigation and/or that have not been approved by the regulatory authorities
Opinions presented during this industry-sponsored webinar are those of the speaker and are not a reflection of Amryt Pharma opinions, nor are they supported, sponsored or endorsed by Amryt Pharma
The presentations are accurate at the time of presentation
Any data about non-Amryt products are based on publicly available information at the time of presentation
Please be aware that information discussed may not be country-specific or may vary from the approved label in the country where you are located or reflect information on an unapproved treatment. Please refer to your local Prescribing Information for full details.